Gerasimos Aravantinos

Dr. Gerasimos Aravantinos

General Oncology Hospital of Kifisia, Athens

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in The Lancet
Verified
Journal Article
Closed access
BBBarbara Ann Burtness
Barbara Ann Burtness
KHKevin J Harrington
Kevin J Harrington
MTMakoto Tahara
Makoto Tahara
GCGilberto de Castro
Gilberto de Castro
APAmanda Psyrri
Amanda Psyrri
JYJeffrey Yorio
Jeffrey Yorio

27 March 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CPCatherine M Phelan
Catherine M Phelan
KKKaroline B Kuchenbaecker
Karoline B Kuchenbaecker
JTJonathan P Tyrer
Jonathan P Tyrer
SKSiddhartha P. Kar
Siddhartha P. Kar
KLKate Lawrenson
Kate Lawrenson
PPPaul Pharoah
Paul Pharoah
Paul Pharoah and colleagues report the results of a large genome-wide association study of ovarian cancer. They identify new susceptibility loci for different epithelial ovarian cancer histotypes and use integrated analyses of genes and regulatory features at each locus to predict candidate susceptibility genes, including OBFC1. To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.

1 February 2003 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JJJ. Janinis
J. Janinis
MPM. Patriki
M. Patriki
LVL. Vini
L. Vini
GAGerasimos Aravantinos
Gerasimos Aravantinos
JWJ. S. Whelan
J. S. Whelan
Background: Despite the use of surgery and radiotherapy, 20–35% of patients with aggressive fibromatosis (AF) will have local recurrence. The purpose of this review was to collect and analyze all available information regarding the role of non-cytotoxic and cytotoxic chemotherapy in AF that has been accumulated over the past few decades. Patients and methods: A systematic review of published clinical trials, studies and case series was carried out using the Medline Express Databases and the Cochrane Collaboration Database from 1970 to October 2000. Results: Most studies published in the literature are in the form of successful case reports and single-arm series with small patient numbers. Most commonly used agents include hormonal agents, non-steroidal anti-inflammatory drugs (NSAIDs), interferons and cytotoxics. The literature data support the use of hormonal agents. Several questions, however, remain unresolved, such as which is the most suitable endocrine manipulation and what is the optimal dose and duration of treatment. NSAIDs and interferons have demonstrated activity against AF either alone or in combination with hormone therapy or chemotherapy but the precise mechanism of action is still unknown. Finally, there is growing evidence in the literature that chemotherapy is effective against AF with almost one in two patients being likely to respond. Conclusions: The evidence in the literature supports the opinion that both non-cytotoxic and cytotoxic chemotherapies are effective against AF. However, the lack of sufficient patient numbers and randomized trials compromises the validity of the reported results and mandates further investigation with properly designed prospective studies including larger patient numbers, with main end points to include not only tumor response rate and survival but also quality-of-life issues.

19 May 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ERE. Razis
E. Razis
MBMattheos Bobos
Mattheos Bobos
VKV. Kotoula
V. Kotoula
AEA. G. Eleftheraki
A. G. Eleftheraki
HKH. P. Kalofonos
H. P. Kalofonos
GFG. Fountzilas
G. Fountzilas

15 January 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Aristotle BamiasAristotle Bamias
Aristotle Bamias
GAGerasimos Aravantinos
Gerasimos Aravantinos
CDC Deliveliotis
C Deliveliotis
DBD Bafaloukos
D Bafaloukos
CKC Kalofonos
C Kalofonos
HGHellenic Cooperative Oncology Group
Hellenic Cooperative Oncology Group
Purpose: The combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) represents the standard regimen for inoperable or metastatic urothelial cancer, but its toxicity is significant. We previously reported a 52% response rate (RR) using a docetaxel and cisplatin (DC) combination. The toxicity of this regimen compared favorably with that reported for MVAC. We thus designed a randomized phase III trial to compare DC with MVAC. Patients and Methods: Patients with inoperable or metastatic urothelial carcinoma; adequate bone marrow, renal, liver, and cardiac function; and Eastern Cooperative Oncology Group performance status ≤ 2 were randomly assigned to receive MVAC at standard doses or docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks. All patients received prophylactic granulocyte colony-stimulating factor (G-CSF) support. Results: Two hundred twenty patients were randomly assigned (MVAC, 109 patients; DC, 111 patients). Treatment with MVAC resulted in superior RR (54.2% v 37.4%; P = .017), median time to progression (TTP; 9.4 v 6.1 months; P = .003) and median survival (14.2 v 9.3 months; P = .026). After adjusting for prognostic factors, difference in TTP remained significant (hazard ratio [HR], 1.61; P = .005), whereas survival difference was nonsignificant at the 5% level (HR, 1.31; P = .089). MVAC caused more frequent grade 3 or 4 neutropenia (35.4% v 19.2%; P = .006), thrombocytopenia (5.7% v 0.9%; P = .046), and neutropenic sepsis (11.6% v 3.8%; P = .001). Toxicity of MVAC was considerably lower than that previously reported for MVAC administered without G-CSF. Conclusion: MVAC is more effective than DC in advanced urothelial cancer. G-CSF-supported MVAC is well tolerated and could be used instead of classic MVAC as first-line treatment in advanced urothelial carcinoma.

8 August 2006 in British Journal of Cancer
Verified
Journal Article
Open access
GSG P Stathopoulos
G P Stathopoulos
KSK Syrigos
K Syrigos
GAGerasimos Aravantinos
Gerasimos Aravantinos
APA Polyzos
A Polyzos
PPP Papakotoulas
P Papakotoulas
VGV Georgoulias
V Georgoulias
Our purpose was to determine the response rate and median and overall survival of gemcitabine as monotherapy versus gemcitabine plus irinotecan in advanced or metastatic pancreatic cancer. Patients with histologically or cytologically confirmed adenocarcinoma who were chemotherapy and radiotherapy naive were enrolled. Patients were centrally randomised at a one-to-one ratio to receive either gemcitabine monotherapy (900 mg m−2 on days 1, 8 and 15 every 4 weeks (arm G), or gemcitabine (days 1 and 8) plus irinotecan (300 mg m−2 on day 8) (arm IG), repeated every 3 weeks. The total number of cycles administered was 255 in the IG arm and 245 in the G arm; the median number of cycles was 3. In all, 145 patients (71 in arm IG and 74 in arm G) were enrolled; 60 and 70 patients from arms IG and G, respectively, were evaluable. A complete clinical response was achieved in three (4.3%) arm G patients; nine (15%) patients in arm IG and four (5.7%) in arm G achieved a partial response. The overall response rate was: arm IG 15% and arm G 10% (95% CI 5.96–24.04 and 95% CI 2.97–17.03, respectively; P=0.387). The median time to tumour progression was 2.8 months and 2.9 months and median survival time was 6.4 and 6.5 months for the IG and G arms, respectively. One-year survival was 24.3% for the IG arm and 21.8% for the G arm. No statistically significant difference was observed comparing gemcitabine monotherapy versus gemcitabine plus irinotecan in the treatment of advanced pancreatic cancer, with respect to overall and 1-year survival.